ACT availability (percentage of outlets stocking at least one ACT for patients of any age) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Very low
ACT price (change in ACT prices for children under 5 years)c · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 1 participants
High
ACT market share (volume of ACTs purchased as a proportion of all antimalarials purchased; all age groups) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 2 participants
High
Use of older antimalarials (amodiaquine, sulphadoxine‐pyrimethamine; children under 5 years) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
no estimate extracted
1 study · 1 participants
High
Adverse effects (such as the number of people receiving ACTs who do not have malaria) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
ACT access (percentage of illness episodes treated with ACTs; all age groups) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
ACT targeting (percentage of ACT takers who are malaria positive; all age groups) · Patients seeking treatment for suspected uncomplicated malaria
1 finding from 1 review
Remaining parasitaemic at 24 hours · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT leads to lower remaining parasitaemic at 24 hours compared with CQ (high certainty).
1 finding from 1 review
Remaining febrile after 24 hours · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT probably leads to lower remaining febrile after 24 hours compared with CQ (moderate certainty).
1 finding from 1 review
Effective treatment of the blood stage parasite As assessed by: Recurrent parasitaemia before day 28 · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT showed no clear difference in effective treatment of the blood stage parasite As assessed by:… compared with CQ (high certainty).
1 finding from 1 review
Post‐treatment prophylaxis As assessed by: Recurrent parasitaemia between day 28 and day 42/56/63 · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT may leads to lower post‐treatment prophylaxis As assessed by: Recurrent parasitaemia… compared with CQ (low certainty).
1 finding from 1 review
Serious adverse events · Adults and children with uncomplicated P. vivax malaria
Summary of findings: ACT showed no clear difference in serious adverse events compared with CQ (high certainty).
1 finding from 1 review
Effective treatment of the blood stage parasite As assessed by: Recurrent parasitaemia before day 28 · Adults and children with uncomplicated P. vivax malaria
Summary of findings: DHA‐P probably leads to lower effective treatment of the blood stage parasite As assessed by:… compared with alternative ACTs (moderate certainty).
1 finding from 1 review
Post treatment prophylaxis As assessed by: Recurrent parasitaemia between day 28 and 42 · Adults and children with uncomplicated P. vivax malaria
Summary of findings: DHA‐P may leads to lower post‐treatment prophylaxis As assessed by: Recurrent parasitaemia… compared with alternative ACTs (low certainty).
1 finding from 1 review
Outcomes · Studies recruited adults and adolescents aged 12 and older with chronic asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations needing hospitalisation · Studies recruited adults and adolescents aged 12 and older with chronic asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations requiring oral corticosteroids ‐ adults · Studies recruited adults and adolescents aged 12 and older with chronic asthma
SiT for maintenance/relief leads to lower patients with exacerbations requiring oral steroids compared with higher‐dose ICS/LABA + SABA (high certainty).
1 finding from 1 review
OR 0.75 [0.65, 0.87]
9096 participants
High
Patients with serious adverse events · Studies recruited adults and adolescents aged 12 and older with chronic asthma
SiT for maintenance/relief showed no clear difference in patients with serious adverse events compared with higher‐dose ICS/LABA + SABA (moderate certainty).
1 finding from 1 review
OR 0.92 [0.74, 1.13]
9130 participants
Moderate
Patients with severe exacerbations (requiring hospitalisation or ER visit) · Studies recruited adults and adolescents aged 12 and older with chronic asthma
SiT for maintenance/relief leads to lower patients with severe exacerbations (requiring hospitalisation or ER… compared with higher‐dose ICS/LABA + SABA (high certainty).
1 finding from 1 review
OR 0.72 [0.57, 0.9]
7768 participants
High
All‐cause mortality · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
It is very uncertain whether d4T changes mortality compared with AZT (very low certainty).
1 finding from 1 review